Media Coverage

Jaguar Q2 revenues boosted by collaborations


Aug 15, 2017 - Animal Pharm

By Sian Lazell
Animal Pharm
August 15, 2017 

Total sales in Q2 reached $896,521, consisting of product revenues of $61,445 (up by 154.5%) and income from collaborations of $835,076 (not included in Q2 2016). In terms of revenues from collaborations, Jaguar has received upfront payments and reimbursements from Elanco as part of a sales agreement for Canalevia.

Jaguar recorded Neonorm revenues of $61,445 in Q2 – an increase of 154%. Neonorm Calf and Neonorm Foal are the firm's lead products for the treatment of diarrhea.

The company – formerly known as Jaguar Animal Health – said operating expenses were down by 5% to $3.2 million, including decreased R&D expenses of $926,791 (-52.5%). However, operating expenses included increased general and administrative expenses of $2.1m (+51%).

Net loss for the period was $1.8m, which was half the size of the loss recorded during the corresponding three months of 2016.

Half year witness similar jump

Total revenues in the first half of the year came in at $1.7m compared to $62,289 recorded during the same time last year. This included product revenues of $135,989.

Neonorm sales reached $105,989 in the first half of the year, which was a 70% year-on-year improvement.

In contrast to Q2, operating expenses were up 11% H1 to $7.9m. This included R&D expenses of $2.2m (-41%) and general and administrative expenses of $5.4m (+70%).

First-half net loss was $6.5m, compared to $7.6m at this stage last year.

Jaguar recently completed a merger with Napo Pharmaceuticals. The terms of the merger included additional funding for the combined company, at $0.925 per share.

Jaguar's next expected veterinary product launch will be for Equilevia, a personalized, non-prescription proprietary gut health product for equine athletes. Jaguar entered an evaluation period with an unnamed multinational company for Equilevia in March.

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum